LifeStance Health: Q3 Earnings Snapshot

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

LifeStance Health Group (LFST) reported Q3 2026 revenue of $455.9M, up 25% YoY, driven by higher patient visits and clinician growth. Net income rose to $22.4M. The company raised its full-year 2026 outlook, expecting revenue of $1.741B-$1.761B. LFST stock closed at $14.21, up 6.28%.

LifeStance Health Group reported Q3 2026 revenue of $455.9M, beating estimates by 5.6% and growing 25.3% YoY. EPS and EBITDA also exceeded expectations. The company raised Q4 and full-year guidance, with operating margins improving to 7.3% from 2% YoY. Sales volumes rose 10.8% YoY, consistent with the prior year.